ArticleCurrent oncology (Toronto, Ont.)2022

Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients.

Ming-Wei Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.